D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
The differential effects of dopamine on striatonigral and striatopallidal neurons are mediated by their specific expression of D1 and D2 dopamine receptor subtypes, respectively.
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- J. Sevigny, P. Chiao, A. Sandrock
- 31 August 2016
In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner, accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores.
Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models
- H. Inoue, Ling Lin, O. Isacson
- Biology, ChemistryProceedings of the National Academy of Sciences
- 4 September 2007
Results show that inhibitory agents of LINGO-1 activity can protect DA neurons against degeneration and indicate a role for the leucine-rich repeat protein LINGo-1 and related classes of proteins in the pathophysiological responses of midbrain DA neurons in PD.
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration
Multiple actions of systemic artemin in experimental neuropathy
- L. Gardell, Ruizhong Wang, F. Porreca
- BiologyNature Network Boston
- 5 October 2003
It is shown that systemic, intermittent administration of artemin produces dose- and time-related reversal of nerve injury–induced pain behavior, together with partial to complete normalization of multiple morphological and neurochemical features of the injury state.
Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil
- T. Engber, E. Koury, S. A. Dennis, M. S. Miller, P. Contreras, R. Bhat
- Biology, PsychologyNeuroscience Letters
- 30 January 1998
cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons
- Y. Sasaki, T. Engber, A. Diantonio
- BiologyExperimental Neurology
- 19 February 2020
Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade
Motor response complications and the function of striatal efferent systems
- T. Chase, M. Mouradian, T. Engber
- Psychology, BiologyNeurology
- 1 December 1993
To the extent that similar alterations contribute to the appearance of motor complications, the successful symptomatic therapy of Parkinson's disease may require continuous dopaminergic stimulation, as well as direct pharmacologic targeting of striatal dopaminoceptive systems.